Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity.

Abstract

OBJECTIVE:

The aim of this study was to assess the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE) compared to normothermic chemoperfusion of the pleural cavity (NCPC), and to investigate the better treatment to control MPE.

METHODS:

Malignant pleural effusion patients were enrolled in the study and treated with NCPC or IPHC under video-assisted thoracoscopic surgery (VATS). The chest drainage duration, clinical characteristics, and recurrence time of pleural effusion of patients were collected for statistical analysis. The chi-squared test and the Fisher's exact test were applied to compare the distribution differences in categorical variables. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and was compared by the log-rank test. The survival analysis was performed using the Cox proportional hazards method.

RESULTS:

A total of 37 MPE patients were enrolled in this study. Twenty-seven patients received NCPC and 10 patients received IPHC under VATS. Significant differences were found in pathological types (p = 0.011), chest drainage duration (p = 0.005), and remission rate (p = 0.009) between two different treatment groups. The chest drainage duration of IPHC under VATS was shorter than the NCPC group (t = 2.969, p = 0.005). The remission rate of MPE in IPHC group was better than the NCPC one (OR = 0.031, 95% CI: 0.002-0.507, p = 0.015). The result of the Kaplan-Meier method showed that IPHC group could significantly prolong the PFS of patients with MPE compared to NCPC group (log-rank p = 0.002). Univariate cox regression analysis showed that patients with MPE in the IPHC group presented significant longer PFS than the NCPC group (HR = 0.264, 95% CI: 0.098-0.713, p = 0.009). Multivariate cox regression analysis further verified this conclusion (HR = 0.268, 95% CI: 0.096-0.753, p = 0.012).

CONCLUSION:

Compared to the NCPC, the IPHC under VATS presents a better control effect on MPE, shorter tube placement time, and longer complete remission time. For this reason, we recommend IPHC under VATS as the first-line treatment for patients with MPE those who can tolerate minimally invasive surgery.

• Authors: Yejun Cao, Qiying Zhang, Zhiyuan Huang, Zhengjun Chai, Jie Liu, Jinyi Wang, Zhengliang Sun, Tian Zhao, Guangxue Wang, Guohan Chen, Yang Han, Qinchuan Li, Xuan Hong
• Journal: Cancer medicine (Cancer Med) Vol. 11 Issue 2 Pg. 348-357 (01 2022) ISSN: 2045-7634 [Electronic] United States
• PMID: 34854253 (Publication Type: Case Reports, Comparative Study, Journal Article)
• Copyright: © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Chemical References

• Antineoplastic Agents

Topics

• Aged
• Antineoplastic Agents (administration & dosage)
• Female
• Humans
• Hyperthermia, Induced
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Perfusion (adverse effects, methods)
• Pleural Cavity (drug effects)
• Pleural Effusion, Malignant (therapy)
• Proportional Hazards Models
• Thoracic Surgery, Video-Assisted
• Treatment Outcome